A MedTech company behind gene-editing technology has raised £5.6 million in seed financing. Pencil Biosciences is developing a fully synthetic gene modulation and editing platform that it says will have impact across a wide range of applications, including new therapeutic options for patients with rare diseases and cancer. The company, based in Alderley Park, Cheshire, … Continue reading £5.6m funding to sharpen Pencil’s gene-editing tech